Plain-English translation of NCT07689058 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment called autologous BCMA-directed cells for people with multiple myeloma that has come back or stopped responding to standard treatments. Researchers take some of your own immune cells, modify them in the laboratory to recognize and attack cancer cells, and then give them back to you. The goal is to see if this approach can help control the disease when other treatments have not worked.
Multiple myeloma is a serious blood cancer that can stop responding to standard medicines over time. Patients who reach this point have very few options left. This medication represents a newer approach that works differently from traditional treatments, and researchers want to test whether it can help people in Pakistan who have exhausted other options.
You likely qualify if…
You likely don't qualify if…
First, you will go through a screening phase lasting up to 28 days to make sure the treatment is safe for you. Then, doctors will collect some of your blood cells through a process called apheresis. Your cells are sent away to be modified in a laboratory. Once the modified cells are ready, you will receive them back through an infusion. You will need regular follow-up visits to monitor how you respond to the treatment and watch for any side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Pakistan